43 completed, 10 unknown, 3 not yet recruiting, 2 active not recruiting. 61 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 61 | Completed 43, Unknown 10, Not yet recruiting 3, Active not recruiting 2, Terminated 2, Recruiting 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Active not recruiting 1 |
Follow Safety Issues: new trials by email Literature Review of Safety Issues trials Research Report on Safety Issues
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study to Evaluate RG002C0106 Injection in Healthy Participants RG002C0106, 0.9% sodium chloride injection - Safety Issues | Phase 1 | Not yet recruiting | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 30 | 2026-12-10 | 2026-10-28 |
| Safety, Tolerability and Pharmacokinetics of ETD-001 Gel Dose 1, dose 2, dose 3 - Safety Issues | Phase 1 | Completed | Etern Therapeutics Wuxi Limited | 56 | 2026-03-16 | 2026-09-10 |
| Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects SSS55 - Safety Issues | Phase 1 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 26 | 2025-08-04 | 2026-03-02 |
| Single Ascending Dose and Multiple Ascending Dose Study of AVR-48 AVR-48, Placebo - Safety Issues, Tolerability | Phase 1 | Not yet recruiting | AyuVis Research, Inc. | 48 | 2025-06-01 | 2025-04-06 |
| Study to Evaluate LPH-5 in Healthy Subjects LPH-5, Placebo - Safety Issues, Tolerance | Phase 1 | Not yet recruiting | Lophora | 48 | 2025-04-30 | 2024-12-09 |
| Bioequivalence Study of Iron Sucrose Injection in Healthy Participants Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer), Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) - Bioequivalency, Safety Issues | Phase 1 | Completed | Sichuan Huiyu Pharmaceutical Co., Ltd | 48 | 2024-11-22 | 2025-03-24 |
| A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults RG002C0106 - Safety Issues | Phase 1 | Completed | Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 50 | 2024-10-18 | 2026-10-15 |
| Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer), Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) - Bioequivalency, Safety Issues | Phase 1 | Completed | Sichuan Huiyu Pharmaceutical Co., Ltd | 48 | 2024-06-25 | 2024-10-08 |
| Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults FC-12738, Saline - Safety Issues, Tolerance | Phase 1 | Completed | Neurodegenerative Disease Research Inc | 24 | 2024-02-20 | 2025-05-25 |
| Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study TAF/EVG rectal insert, Matching placebo rectal insert - Safety Issues | Phase 1 | Completed | Eastern Virginia Medical School | 21 | 2024-01-16 | 2025-07-25 |
| Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert TAF/EVG vaginal insert, Matching Placebo vaginal insert - Safety Issues | Phase 1 | Completed | Eastern Virginia Medical School | 68 | 2023-11-08 | 2025-09-02 |
| A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults ICM20, Benznidazole - Safety Issues | Phase 1 | Completed | IC-MedTech Corporation | 13 | 2023-08-20 | 2026-04-16 |
| Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®. GP40221, ozempic - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Geropharm | 120 | 2023-06-30 | 2024-07-11 |
| Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients OmniMSC-AMI - Safety Issues | Phase 1 | Terminated | Taiwan Bio Therapeutics Inc. | 1 | 2023-06-26 | 2026-07-06 |
| SB17170 Phase1 Trial in Healthy Volunteer SB17170, Placebo - Safety Issues, Tolerability | Phase 1 | Completed | SPARK Biopharma | 64 | 2023-05-24 | 2024-03-21 |
| Safety and Tolerability of DMT in Healthy Adults N,N-Dimethyltryptamine, Placebo - Safety Issues, Healthy Volunteers | Phase 1 | Completed | Universidade Federal do Rio Grande do Norte | 25 | 2023-04-26 | 2023-10-11 |
| Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes controlled-ileal-release nicotinic acid (SAD/ MAD/MD) single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD), immediate-release nicotinic acid (SAD), Placebo controlled-ileal-release nicotinic acid (SAD/MAD) - Safety Issues, Pharmacokinetic | Phase 1 | Completed | University Hospital Schleswig-Holstein | 60 | 2022-12-19 | 2024-11-27 |
| Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) - Safety Issues, Pharmacokinetics | Phase 1 | Completed | Cinclus Pharma Holding AB | 35 | 2022-11-27 | 2025-01-03 |
| Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis Proglumide, Placebo - Safety Issues, Pain | Phase 1 / Phase 2 | Active not recruiting | Georgetown University | 32 | 2022-11-17 | 2026-08-05 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
Showing 20 of 61. Sign in to see all of them.
Acute Pain (1) · Arthritis, Juvenile (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Asthenia (1) · Brain Injuries (1) · COVID-19 (1) · Cerebral Palsy (1) · Chondrosarcoma (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Dermatitis, Atopic (1) · Diabetes Mellitus (1) · Hemorrhage (1) · Hidradenitis Suppurativa (1)
Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Respiratory Tract Diseases (3) · Signs and Symptoms (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Glucose Metabolism Disorders (2) · Immune System Diseases (2) · Infections (2) · Intestinal Diseases (2)
Sodium Chloride (6) · Lansoprazole (3) · Dexlansoprazole (2) · Drug Evaluation (2) · Ferric Oxide, Saccharated (2) · Long-Term Synaptic Depression (2) · Sagittal Abdominal Diameter (2) · 4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Adalimumab (1) · Bevacizumab (1) · ChulaCov19 vaccine (1) · Clarithromycin (1) · Didanosine (1) · Drug Interactions (1) · Ethanol (1)
First Affiliated Hospital of Zhejiang University (4) · Guangdong Women and Children Hospital (4) · Eastern Virginia Medical School (2) · Laboratorios Richmond S.A.C.I.F. (2) · PT Bio Farma (2) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. (2) · Sichuan Huiyu Pharmaceutical Co., Ltd (2) · University Hospital Schleswig-Holstein (2) · Amgen (1) · Avilex Pharma (1) · AyuVis Research, Inc. (1) · Bavarian Nordic (1) · Cerevance (1) · Chulalongkorn University (1) · Cinclus Pharma Holding AB (1)
United States (20) · China (16) · Germany (3) · Argentina (2) · Australia (2) · Indonesia (2) · Russia (2) · Sweden (2) · Taiwan (2) · Austria (1) · Brazil (1) · Colombia (1) · Finland (1) · Kenya (1) · South Africa (1)
Lihua Wu, Doctor (4) · Jie Yang, PHD (2) · Susanna Nikolaus, Prof. Dr. (2) · Ahad Sabet, MD (1) · Amy Melsaether, MD (1) · Bernie Endyarni, MD (1) · Cassie Grimsley Ackerley, MD, MSc (1) · Chang Yanqun, Phd (1) · Chun Wan (1) · Draulio B. Araujo, Ph.D (1) · Ethel C Feleder, MD (1) · Ethel C. Feleder, MD (1) · Frank Lee, MD, CPI (1) · George J. Atiee, MD (1) · Gustavo F Doncel, MD, PhD (1)
PMID 23673863, PMID 26051681, PMID 31338800, PMID 31598921, PMID 31876334, PMID 32300579, PMID 32757149, PMID 33651243, PMID 38287068, PMID 38794273, PMID 40532423, PMID 41685666
2017 (1), R44DK107231 (1)